ACH 15Alternative Names: ACH15
Latest Information Update: 26 Oct 2016
At a glance
- Originator Ache Laboratories
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 18 Oct 2016 Ache Laboratorios terminates a phase-I clinical trial for inflammation in Brazil (PO) (NCT01702675)
- 04 Jan 2016 Phase-I clinical trials in inflammation in Brazil (PO) prior to January 2016 (Ache laboratories pipeline, January 2016)
- 05 Oct 2012 Preclinical trials in Undefined indication in Brazil (PO)